Published Chronic Lymphocytic Leukemia (CLL) Panel

This panel was designed by Omar Abdel-Wahab Lab at Memorial Sloan Kettering Cancer Center and covers many of the recurrent gene mutations in chronic lymphocytic leukemia (CLL). The panel was featured in a study published in the New England Journal of Medicine, “Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors.” The panel was used to uncover the clonal architecture behind resistance to pirtobrutinib, a new class of non-covalent BTK inhibitors. The study allowed the investigators to identify the co-occurring mutations within each subclone, providing a picture of how new subclones evolved from pre-existing ones in response to therapeutic selective pressure. In addition, the authors found that the resistance mutations to this new class of non-covalent BTK inhibitors could also confer resistance to other non-covalent and covalent BTK inhibitors.